134 related articles for article (PubMed ID: 16619511)
21. EGF-induced apoptosis in A431 cells is dependent on STAT1, but not on STAT3.
Grudinkin PS; Zenin VV; Kropotov AV; Dorosh VN; Nikolsky NN
Eur J Cell Biol; 2007 Oct; 86(10):591-603. PubMed ID: 17646016
[TBL] [Abstract][Full Text] [Related]
22. Neuroendocrine differentiation is involved in chemoresistance induced by EGF in prostate cancer cells.
Li Y; Chen HQ; Chen MF; Liu HZ; Dai YQ; Lv H; Bing Zu X; Qi L
Life Sci; 2009 Jun; 84(25-26):882-7. PubMed ID: 19356736
[TBL] [Abstract][Full Text] [Related]
23. Cell-cycle progression and response of germ cell tumors to cisplatin in vitro.
Mueller S; Schittenhelm M; Honecker F; Malenke E; Lauber K; Wesselborg S; Hartmann JT; Bokemeyer C; Mayer F
Int J Oncol; 2006 Aug; 29(2):471-9. PubMed ID: 16820891
[TBL] [Abstract][Full Text] [Related]
24. [Impact of RNA interference targeting hypoxia-inducible factor-1alpha on chemosensitivity in esophageal squamous cell carcinoma cells under hypoxia].
Wu XA; Sun Y; Fan QX; Wang LX; Wang RL; Zhang L
Zhonghua Yi Xue Za Zhi; 2007 Oct; 87(37):2640-4. PubMed ID: 18162154
[TBL] [Abstract][Full Text] [Related]
25. Cell cycle modulation by hematopoietic growth factors in myelodysplastic syndromes: analysis by three-color flow cytometry.
Ogata K; An E; Kamikubo K; Tamura H; Yokose N; Dan K; Nomura T
Exp Hematol; 1997 Jan; 25(1):8-18. PubMed ID: 8989901
[TBL] [Abstract][Full Text] [Related]
26. Prediction of chemosensitivity using multigene analysis in head and neck squamous cell carcinoma.
Hasegawa Y; Goto M; Hanai N; Ijichi K; Terada A; Hyodo I; Ogawa T; Fukushima M
Oncology; 2007; 73(1-2):104-11. PubMed ID: 18337622
[TBL] [Abstract][Full Text] [Related]
27. Development of head and neck squamous cell carcinoma is associated with altered cytokine responsiveness.
Douglas WG; Tracy E; Tan D; Yu J; Hicks WL; Rigual NR; Loree TR; Wang Y; Baumann H
Mol Cancer Res; 2004 Oct; 2(10):585-93. PubMed ID: 15498933
[TBL] [Abstract][Full Text] [Related]
28. Chemosensitization of oral squamous cell carcinoma cells to cisplatin by histone deacetylase inhibitor, suberoylanilide hydroxamic acid.
Rikiishi H; Shinohara F; Sato T; Sato Y; Suzuki M; Echigo S
Int J Oncol; 2007 May; 30(5):1181-8. PubMed ID: 17390020
[TBL] [Abstract][Full Text] [Related]
29. A case of squamous cell carcinoma of the head and neck producing granulocyte-colony stimulating factor with marked leukocytosis.
Toyoda M; Chikamatsu K; Sakakura K; Fukuda Y; Takahashi K; Miyashita M; Shimamura K; Furuya N
Auris Nasus Larynx; 2007 Jun; 34(2):267-71. PubMed ID: 17097253
[TBL] [Abstract][Full Text] [Related]
30. Epidermal growth factor receptor biology in head and neck cancer.
Kalyankrishna S; Grandis JR
J Clin Oncol; 2006 Jun; 24(17):2666-72. PubMed ID: 16763281
[TBL] [Abstract][Full Text] [Related]
31. System L amino acid transporter inhibitor enhances anti-tumor activity of cisplatin in a head and neck squamous cell carcinoma cell line.
Yamauchi K; Sakurai H; Kimura T; Wiriyasermkul P; Nagamori S; Kanai Y; Kohno N
Cancer Lett; 2009 Apr; 276(1):95-101. PubMed ID: 19058911
[TBL] [Abstract][Full Text] [Related]
32. Effectiveness of pharmacokinetic modulating chemotherapy combined with cisplatin as induction chemotherapy in resectable locally advanced head and neck cancer: phase II study.
Chang PM; Chen PM; Chu PY; Wang LW; Tai SK; Tsai TL; Huang JL; Wang YF; Chang SY; Yang MH
Cancer Chemother Pharmacol; 2008 Dec; 63(1):9-17. PubMed ID: 18343925
[TBL] [Abstract][Full Text] [Related]
33. Does dexamethasone inhibit the antineoplastic effect of cisplatin and docetaxel in head and neck cancer cells?
Wagenblast J; Arnoldner C; Gstöttner W; Bisdas S; Mörtel S; May A; Hambek M
Anticancer Res; 2010 Jan; 30(1):123-7. PubMed ID: 20150626
[TBL] [Abstract][Full Text] [Related]
34. Integrating novel agents into the curative treatment of head and neck cancer.
Haddad R; Allen A; Wirth L; Tishler R; Posner M
Expert Rev Anticancer Ther; 2006 Feb; 6(2):157-9. PubMed ID: 16445367
[No Abstract] [Full Text] [Related]
35. Effects of terbium on the cytotoxicity of cisplatin in FaDu human head and neck squamous cell carcinoma.
Paltoo DN; Canada RG
Cancer Biochem Biophys; 1998 Oct; 16(3):213-27. PubMed ID: 10072206
[TBL] [Abstract][Full Text] [Related]
36. Variations of EGF-R surface expression in squamous cell carcinomas of the head and neck region.
Mandic R; Eikelkamp N; Peldszus R; Sadowski M; Sesterhenn AM; Dünne AA; Werner JA
Anticancer Res; 2001; 21(5):3413-8. PubMed ID: 11848502
[TBL] [Abstract][Full Text] [Related]
37. Effect of reorganized-human growth hormone on cell cycle kinetics in liver cancer in vitro.
He XY; Xu GL; Xu RN; Ze ZM
Hepatobiliary Pancreat Dis Int; 2002 May; 1(2):224-7. PubMed ID: 14607744
[TBL] [Abstract][Full Text] [Related]
38. Enhanced growth inhibition of squamous cell carcinoma of the head and neck by combination therapy of paclitaxel and opioid growth factor.
McLaughlin PJ; Jaglowski JR; Verderame MF; Stack BC; Leure-Dupree AE; Zagon IS
Int J Oncol; 2005 Mar; 26(3):809-16. PubMed ID: 15703840
[TBL] [Abstract][Full Text] [Related]
39. Effect of bortezomib and cetuximab in EGF-stimulated HNSCC.
Wagenblast J; Baghi M; Arnoldner C; Bisdas S; Gstöttner W; Ackermann H; May A; Knecht R; Hambek M
Anticancer Res; 2008; 28(4B):2239-43. PubMed ID: 18751401
[TBL] [Abstract][Full Text] [Related]
40. Inhibition of STAT-3 results in greater cetuximab sensitivity in head and neck squamous cell carcinoma.
Bonner JA; Yang ES; Trummell HQ; Nowsheen S; Willey CD; Raisch KP
Radiother Oncol; 2011 Jun; 99(3):339-43. PubMed ID: 21704410
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
